Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases
Authors
Keywords
-
Journal
Expert Review of Clinical Immunology
Volume 15, Issue 8, Pages 837-848
Publisher
Informa UK Limited
Online
2019-06-11
DOI
10.1080/1744666x.2019.1630273
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation
- (2019) Mark T. Osterman et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Clinical relevance of monitoring serum adalimumab levels in axial spondyloarthritis
- (2019) José Miguel Senabre Gallego et al. RHEUMATOLOGY INTERNATIONAL
- Vedolizumab Trough Levels and Histological Healing During Maintenance Therapy in Ulcerative Colitis
- (2019) Lieven Pouillon et al. Journal of Crohns & Colitis
- Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn’s Disease: A Prospective Multicentre Study
- (2019) Niels Vande Casteele et al. Journal of Crohns & Colitis
- Higher Trough Vedolizumab Concentrations During Maintenance Therapy Are Associated with Corticosteroid-Free Remission in Inflammatory Bowel Disease
- (2019) Ryan Ungaro et al. Journal of Crohns & Colitis
- Proactive Therapeutic Drug Monitoring of Adalimumab Is Associated With Better Long-term Outcomes Compared With Standard of Care in Patients With Inflammatory Bowel Disease
- (2019) Konstantinos Papamichael et al. Journal of Crohns & Colitis
- DOP56 Dashboard driven vs. conventional dosing of infliximab in inflammatory bowel disease patients: the PRECISION trial
- (2019) A Strik et al. Journal of Crohns & Colitis
- DOP45 Adequate infliximab exposure during the induction phase is associated with early complete fistula response in patients with fistulizing Crohn’s disease: a post-hoc analysis of the ACCENT-2 trial
- (2019) N Vande Casteele et al. Journal of Crohns & Colitis
- OP18 Proactive adalimumab trough measurements increase corticosteroid-free clinical remission in paediatric patients with Crohn’s disease: the paediatric Crohn’s disease adalimumab-level-based optimisation treatment (PAILOT) trial
- (2019) A Assa et al. Journal of Crohns & Colitis
- Ustekinumab Exposure-outcome Analysis in Crohn’s Disease Only in Part Explains Limited Endoscopic Remission Rates
- (2019) Bram Verstockt et al. Journal of Crohns & Colitis
- Vedolizumab Concentrations Are Associated with Long-Term Endoscopic Remission in Patients with Inflammatory Bowel Diseases
- (2019) Andres J. Yarur et al. DIGESTIVE DISEASES AND SCIENCES
- Pharmacokinetic parameters of infliximab influence the rate of relapse after de-escalation in adults with inflammatory bowel diseases
- (2019) Antoine Petitcollin et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Concentrations of Ustekinumab During Induction Therapy Associate With Remission in Patients With Crohn’s Disease
- (2019) Ninon Soufflet et al. Clinical Gastroenterology and Hepatology
- Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases
- (2019) Konstantinos Papamichael et al. Clinical Gastroenterology and Hepatology
- Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease
- (2019) David Drobne et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Clinical response correlates with 4‐week post injection ustekinumab concentrations in moderate‐to‐severe psoriasis patients
- (2019) N. Van den Berghe et al. BRITISH JOURNAL OF DERMATOLOGY
- Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn’s Disease
- (2019) Erwin Dreesen et al. Clinical Gastroenterology and Hepatology
- Tu1830 – Infliximab and Adalimumab Concentrations May Vary Between the Enzyme-Linked Immunosorbent Assay and the Homogeneous Mobility Shift Assay in Patients with Inflammatory Bowel Disease
- (2019) William T. Clarke et al. GASTROENTEROLOGY
- Tu1829 – Comparison of Serum Concentrations of Ustekinumab Obtained by Three Commercial Assays in Patients with Crohns Disease
- (2019) Christine Verdon et al. GASTROENTEROLOGY
- Defining a minimal effective serum trough concentration of secukinumab in psoriasis: a step towards personalized therapy
- (2019) Rani Soenen et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study
- (2019) Nicholas A Kennedy et al. Lancet Gastroenterology & Hepatology
- Prospective Observational Evaluation of Time-Dependency of Adalimumab Immunogenicity and Drug Concentrations: The POETIC Study
- (2018) Bella Ungar et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases
- (2018) Bella Ungar et al. Clinical Gastroenterology and Hepatology
- Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases
- (2018) Erwin Dreesen et al. Clinical Gastroenterology and Hepatology
- Biological therapies in inflammatory bowel disease: Beyond anti-TNF therapies
- (2018) Konstantinos H. Katsanos et al. CLINICAL IMMUNOLOGY
- Methotrexate Dose in Patients With Early Rheumatoid Arthritis Impacts Methotrexate Polyglutamate Pharmacokinetics, Adalimumab Pharmacokinetics, and Efficacy: Pharmacokinetic and Exposure-response Analysis of the CONCERTO Trial
- (2018) Sandra L. Goss et al. CLINICAL THERAPEUTICS
- Infliximab trough levels and persistent vs transient antibodies measured early after induction predict long-term clinical remission in patients with inflammatory bowel disease
- (2018) Giorgia Bodini et al. DIGESTIVE AND LIVER DISEASE
- Maintenance Adalimumab Concentrations Are Associated with Biochemical, Endoscopic, and Histologic Remission in Inflammatory Bowel Disease
- (2018) Anna Juncadella et al. DIGESTIVE DISEASES AND SCIENCES
- Using Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: From an Old Concept to a Future Standard of Care?
- (2018) Konstantinos Papamichael et al. GASTROENTEROLOGY
- Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease
- (2018) Omoniyi J. Adedokun et al. GASTROENTEROLOGY
- Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn’s Disease
- (2018) Geert D’Haens et al. GASTROENTEROLOGY
- Association Between Serum Infliximab Trough Concentrations During Maintenance Therapy and Biochemical, Endoscopic, and Histologic Remission in Crohn’s Disease
- (2018) Konstantinos Papamichael et al. INFLAMMATORY BOWEL DISEASES
- Therapeutic Drug Monitoring Guides the Management of Crohn’s Patients with Secondary Loss of Response to Adalimumab
- (2018) Sophie Restellini et al. INFLAMMATORY BOWEL DISEASES
- Proactively Optimized Infliximab Monotherapy Is as Effective as Combination Therapy in IBD
- (2018) Sara Lega et al. INFLAMMATORY BOWEL DISEASES
- Efficacy of Vedolizumab in Fistulising Crohn’s Disease: Exploratory Analyses of Data from GEMINI 2
- (2018) Brian G Feagan et al. Journal of Crohns & Colitis
- Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study
- (2018) Luisa Guidi et al. Journal of Crohns & Colitis
- Proactive Infliximab Monitoring Following Reactive Testing is Associated With Better Clinical Outcomes Than Reactive Testing Alone in Patients With Inflammatory Bowel Disease
- (2018) Konstantinos Papamichael et al. Journal of Crohns & Colitis
- Usefulness and correlation with clinical response of serum ustekinumab levels measured at 6 weeks versus 12 weeks
- (2018) M. Toro-Montecinos et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Drug immunogenicity in patients with inflammatory arthritis and secondary failure to tumour necrosis factor inhibitor therapies: the REASON study
- (2018) Alejandro Balsa et al. RHEUMATOLOGY
- Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naive Crohn's disease patients: the usefulness of rapid testing
- (2018) Bram Verstockt et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Combination Therapy with Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy—a Post-hoc analysis
- (2018) Jean Frederic Colombel et al. Clinical Gastroenterology and Hepatology
- Defining the therapeutic range for adalimumab and predicting response in psoriasis: a multicenter prospective observational cohort study
- (2018) Nina Wilkinson et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Adherence to etanercept therapy in rheumatoid arthritis patients during 3 years of follow-up
- (2018) E. H. Vogelzang et al. PLoS One
- Predictors of relapse following infliximab de-escalation in patients with inflammatory bowel disease: the value of a strategy based on therapeutic drug monitoring
- (2018) Camille Lucidarme et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Infliximab Exposure-Response Relationship and Thresholds Associated with Endoscopic Healing in Patients With Ulcerative Colitis
- (2018) Niels Vande Casteele et al. Clinical Gastroenterology and Hepatology
- American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease
- (2017) Joseph D. Feuerstein et al. GASTROENTEROLOGY
- A Survey Study of Gastroenterologists’ Attitudes and Barriers Toward Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease
- (2017) Laurie B Grossberg et al. INFLAMMATORY BOWEL DISEASES
- Therapeutic Drug Monitoring During Induction of Anti–Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease
- (2017) Konstantinos Papamichael et al. INFLAMMATORY BOWEL DISEASES
- Therapeutic Drug Monitoring to Guide Infliximab Dose Adjustment is Associated with Better Endoscopic Outcomes than Clinical Decision Making Alone in Active Inflammatory Bowel Disease
- (2017) Orlaith B. Kelly et al. INFLAMMATORY BOWEL DISEASES
- Correlation between trough serum levels of adalimumab and absolute PASI score in a series of patients with psoriasis
- (2017) J. M. Carrascosa et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment
- (2017) Joachim R. Kalden et al. Nature Reviews Rheumatology
- Correction: The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study
- (2017) Robert J. Moots et al. PLoS One
- Prolongation of Biologic Dosing Intervals in Patients With Stable Psoriasis
- (2017) Ji S. van Bezooijen et al. THERAPEUTIC DRUG MONITORING
- High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort
- (2016) Meghna Jani et al. ANNALS OF THE RHEUMATIC DISEASES
- Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis
- (2016) Konstantinos Papamichael et al. Clinical Gastroenterology and Hepatology
- Variability in Golimumab Exposure: A ‘Real-Life’ Observational Study in Active Ulcerative Colitis
- (2016) Iris Detrez et al. Journal of Crohns & Colitis
- Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies
- (2016) Omoniyi J. Adedokun et al. Journal of Crohns & Colitis
- Post-Induction Adalimumab Concentration is Associated with Short-Term Mucosal Healing in Patients with Ulcerative Colitis
- (2016) Konstantinos Papamichael et al. Journal of Crohns & Colitis
- Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
- (2016) A. Menter et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Search for a concentration–effect curve of adalimumab in ankylosing spondylitis patients
- (2016) AF Marsman et al. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
- Serum tocilizumab trough concentration can be used to monitor systemic IL-6 receptor blockade in patients with rheumatoid arthritis: a prospective observational cohort study
- (2016) EL Kneepkens et al. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
- Positive correlation between etanercept concentration and the decrease in Psoriasis Area and Severity Index scale value
- (2016) Laida Elberdín et al. International Journal of Clinical Pharmacy
- Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis
- (2016) Désirée van der Heijde et al. Arthritis & Rheumatology
- Rapid Test for Infliximab Drug Concentration Allows Immediate Dose Adaptation
- (2016) Thomas Van Stappen et al. Clinical and Translational Gastroenterology
- Towards optimal cut-off trough levels of adalimumab and etanercept for a good therapeutic response in rheumatoid arthritis. Results of the INMUNOREMAR study
- (2015) Raimon Sanmarti et al. ANNALS OF THE RHEUMATIC DISEASES
- The correlation of clinical efficacy, serum trough levels and antidrug antibodies in ustekinumab-treated patients with psoriasis in a clinical-practice setting
- (2015) S.P. Menting et al. BRITISH JOURNAL OF DERMATOLOGY
- Long-Term Outcome of Patients With Crohn’s Disease Who Discontinued Infliximab Therapy Upon Clinical Remission
- (2015) Konstantinos Papamichael et al. Clinical Gastroenterology and Hepatology
- Levels of Drug and Antidrug Antibodies Are Associated With Outcome of Interventions After Loss of Response to Infliximab or Adalimumab
- (2015) Henit Yanai et al. Clinical Gastroenterology and Hepatology
- Withdrawal of Immunomodulators After Co-treatment Does Not Reduce Trough Level of Infliximab in Patients With Crohn’s Disease
- (2015) David Drobne et al. Clinical Gastroenterology and Hepatology
- Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
- (2015) Niels Vande Casteele et al. GASTROENTEROLOGY
- Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis
- (2015) Johannan F. Brandse et al. GASTROENTEROLOGY
- Practical guidance on immunogenicity to biologic agents used in the treatment of psoriasis: What can be learnt from other diseases?
- (2015) Jo Lambert et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Drug trough levels predict therapeutic responses to dose reduction of adalimumab for rheumatoid arthritis patients during 24 weeks of follow-up
- (2015) Der-Yuan Chen et al. RHEUMATOLOGY
- Developing a Therapeutic Range of Adalimumab Serum Concentrations in Management of Psoriasis
- (2015) Stef P. Menting et al. JAMA Dermatology
- Clinical Utility of Random Anti-Tumor Necrosis Factor Drug-Level Testing and Measurement of Antidrug Antibodies on the Long-Term Treatment Response in Rheumatoid Arthritis
- (2015) Meghna Jani et al. Arthritis & Rheumatology
- Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis
- (2014) F. Baert et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Development of an Algorithm Incorporating Pharmacokinetics of Adalimumab in Inflammatory Bowel Diseases
- (2014) Xavier Roblin et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis
- (2014) Der-Yuan Chen et al. ANNALS OF THE RHEUMATIC DISEASES
- Anti-adalimumab antibodies and adalimumab concentrations in psoriatic arthritis; an association with disease activity at 28 and 52 weeks of follow-up
- (2014) Erik H Vogelzang et al. ANNALS OF THE RHEUMATIC DISEASES
- Golimumab trough levels, antidrug antibodies and clinical response in patients with rheumatoid arthritis treated in daily clinical practice
- (2014) Eva L Kneepkens et al. ANNALS OF THE RHEUMATIC DISEASES
- Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24 weeks of follow-up
- (2014) E L Kneepkens et al. ANNALS OF THE RHEUMATIC DISEASES
- Early Trough Levels and Antibodies to Infliximab Predict Safety and Success of Reinitiation of Infliximab Therapy
- (2014) Filip Baert et al. Clinical Gastroenterology and Hepatology
- Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis
- (2014) Omoniyi J. Adedokun et al. GASTROENTEROLOGY
- Proactive Therapeutic Concentration Monitoring of Infliximab May Improve Outcomes for Patients with Inflammatory Bowel Disease
- (2014) Byron P. Vaughn et al. INFLAMMATORY BOWEL DISEASES
- Adalimumab serum levels and antidrug antibodies towards adalimumab in peripheral spondyloarthritis: no association with clinical response to treatment or with disease relapse upon treatment discontinuation
- (2014) Jacqueline E Paramarta et al. ARTHRITIS RESEARCH & THERAPY
- Key findings towards optimising adalimumab treatment: the concentration–effect curve
- (2013) Mieke F Pouw et al. ANNALS OF THE RHEUMATIC DISEASES
- Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up
- (2013) Eva L Kneepkens et al. ANNALS OF THE RHEUMATIC DISEASES
- The combined use of disease activity and infliximab serum trough concentrations for early prediction of (non-)response to infliximab in rheumatoid arthritis
- (2013) Bart J. F. van den Bemt et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study
- (2013) S.K. Mahil et al. BRITISH JOURNAL OF DERMATOLOGY
- Influence of neutralizing antibodies to adalimumab and infliximab on the treatment of psoriasis
- (2013) T. Bito et al. BRITISH JOURNAL OF DERMATOLOGY
- Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial
- (2013) Casper Steenholdt et al. GUT
- Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab
- (2012) Chamaida Plasencia et al. ANNALS OF THE RHEUMATIC DISEASES
- Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis
- (2012) Hidetoshi Takahashi et al. JOURNAL OF DERMATOLOGY
- Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients
- (2011) A Jamnitski et al. ANNALS OF THE RHEUMATIC DISEASES
- Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis
- (2011) D. Pascual-Salcedo et al. RHEUMATOLOGY
- Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases
- (2011) Emilie Ducourau et al. ARTHRITIS RESEARCH & THERAPY
- Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis
- (2010) A. W. R. van Kuijk et al. ANNALS OF THE RHEUMATIC DISEASES
- The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept
- (2010) A. Jamnitski et al. ANNALS OF THE RHEUMATIC DISEASES
- Circulating concentration of infliximab and response to treatment in ankylosing spondylitis: Results from a randomized control study
- (2009) Roman Krzysiek et al. ARTHRITIS AND RHEUMATISM
- Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis
- (2008) T R D J Radstake et al. ANNALS OF THE RHEUMATIC DISEASES
- Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis
- (2008) M K de Vries et al. ANNALS OF THE RHEUMATIC DISEASES
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started